Related Experiment Video

Updated: Sep 26, 2026

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm
06:18

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm

Published on: September 17, 2021

Celiprolol increases coronary blood flow and reduces severity of myocardial ischemia via nitric oxide release

Hiroshi Asanuma1, Koichi Node, Tetsuo Minamino

  • 1Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.

Journal of Cardiovascular Pharmacology
|March 27, 2003
PubMed

Insights

Celiprolol enhances coronary blood flow and cardiac function in ischemic hearts by increasing nitric oxide (NO) release, independent of beta-adrenoceptor blockade. This suggests a novel NO-dependent mechanism for improving myocardial ischemia.

Area of Science:

  • Cardiovascular Pharmacology
  • Myocardial Ischemia Research
  • Nitric Oxide Signaling

Background:

  • Celiprolol, a beta(1)-adrenoceptor antagonist, is known for its antihypertensive effects and ability to increase renal nitric oxide (NO) levels.
  • The role of celiprolol in modulating cardiac NO release and coronary blood flow (CBF) in the context of myocardial ischemia remains to be fully elucidated.

Purpose of the Study:

  • To investigate whether celiprolol increases coronary blood flow (CBF) by augmenting cardiac NO release in an in vivo model of myocardial ischemia.
  • To determine the role of NO synthase and beta-adrenoceptor subtypes in mediating the effects of celiprolol on cardiac function and hemodynamics.

Main Methods:

  • Anesthetized open-chest dogs underwent surgical reduction of coronary perfusion pressure to induce myocardial ischemia (CBF reduced to 60% of control).
  • Celiprolol was infused into the left anterior descending coronary artery, and measurements included CBF, fractional shortening, lactate extraction ratio, and cardiac NO release.
  • The effects of celiprolol were assessed in the presence and absence of L-nitroarginine methyl ester (a nitric oxide synthase inhibitor) and ICI 118551 (a beta(2)-adrenoceptor antagonist). Propranolol (a nonselective beta-adrenoceptor antagonist) was also used.

Main Results:

  • Celiprolol infusion significantly increased CBF, fractional shortening, and lactate extraction ratio without altering coronary perfusion pressure.
  • Celiprolol administration led to increased cardiac NO release, which was attenuated by L-nitroarginine methyl ester.
  • The beneficial effects of celiprolol were not affected by ICI 118551, and propranolol did not alter CBF or cardiac NO release, indicating a beta-adrenoceptor blockade-independent mechanism.

Conclusions:

  • Celiprolol mediates coronary vasodilation and improves myocardial ischemia through NO-dependent mechanisms.
  • The observed cardiovascular effects of celiprolol are independent of beta-adrenoceptor antagonism.
  • Celiprolol represents a potential therapeutic agent for managing myocardial ischemia via enhanced nitric oxide production.

More Related Videos

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...